The D6.1 Deliverable: website and communication tools, provides the structure and management of the PharmaLedger website (accessible at https://pharmaledger.eu/), as well as a description of the different communication tools that the PharmaLedger project is setting up for the online interaction through project lifecycle. More specifically this deliverable contains: • The logo of the project to be used in dissemination and communication activities • The project website, including the selected domains, its design and initial content. • The communication tools to be used in the project, both internally and externally. These include the templates to be used for presentations and reports, the selected internal collaboration tool in the project, and the activities in terms of the use of external tools like social media. Currently a land page website has been created while the official project website is being designed to be developed and deployed. This deliverable describes the structure of both websites, as well as the different content management and technical considerations being treated. Tools and the procedures for communications are fully described in deliverable D7.1 Project Reference Manual and Quality Plan.

1. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 853992
Copyright © PharmaLedger Consortium 2020 – 2023 PharmaLedger contact@pharmaledger.eu
D6.1 Website and Communication Tool
Deliverable No D6.1
Work package No. and Title WP6 Culture and Adoption (Task 6.5 Dissemination and Communication)
Version - Status V3.0
Date of Issue 31/03/2020
Dissemination Level PUBLIC (PU)
Filename D6.1 Deliverable website and communication tool_v3.0_final
Ref. Ares(2020)1862314 - 31/03/2020

2. PharmaLedger – 853992 | Deliverable D6.1 v3.0 | PUBLIC 2/13
DOCUMENT INFO
Authors
Author Organization
Clarisse DIAS da MOTA NVS
Tamanna KHAN TVS
María Eugenia BELTRAN UPM
Cecilia VERA UPM
Document History
Date Version Editor Change Status
20/03/2020 1.0 Clarisse Dias da Mota Initial draft version draft
27/03/2020 1.1 Tamanna Khan, Cecilia Vera,
María Eugenia Beltrán
Updated document with new
content
draft
30/03/2020 1.2 Clarisse Dias da Mota,
Tamanna Khan
Revisions and comments
approached
draft
30/03/2020 1.3 Martin Robison Revision and commenting draft
31/03/2020 2.0 Cecilia Vera, María Eugenia
Beltrán
Final revision of the
deliverable
Final
31/03/2020 2.1 Martin Robison Review and Proof reading Final
31/03/2020 2.2 Clarisse Dias da Mota,
Tamanna Khan
Revisions and comments
approached
Final
31/03/2020 3.0 Clarisse Dias da Mota,
Tamanna Khan; Cecilia Vera,
María Eugenia Beltrán
Revisions and comments
approached
Final

3. PharmaLedger – 853992 | Deliverable D6.1 V3.0 | PUBLIC 3/13
TABLE OF CONTENT
EXECUTIVE SUMMARY..................................................................................................................................4
1. INTRODUCTION.....................................................................................................................................5
2. VISUAL IDENTITY: PHARMALEDGER BRAND AND LOGO.......................................................................5
3. PharmaLedger WEB SITE.......................................................................................................................6
3.1 Website Domain ...........................................................................................................................6
3.2 Initial landing page or website setup............................................................................................6
3.3 Design and development of the PharmaLedger website .............................................................9
3.4 Website Content Management ..................................................................................................10
3.5 Monitoring and control...............................................................................................................11
3.6 Website Technical Aspects .........................................................................................................11
3.7 Security and back-up...................................................................................................................11
4. COMMUNICATION TOOLS...................................................................................................................11
4.1 Internal communication tools.....................................................................................................11
4.2 External communication tools....................................................................................................12

4. PharmaLedger – 853992 | Deliverable D6.1 V3.0 | PUBLIC 4/13
EXECUTIVE SUMMARY
The D6.1 Deliverable: website and communication tools, provides the structure and management of the
PharmaLedger website (accessible at https://pharmaledger.eu/), as well as a description of the different
communication tools that the PharmaLedger project is setting up for the online interaction through
project lifecycle.
More specifically this deliverable contains:
• The logo of the project to be used in dissemination and communication activities
• The project website, including the selected domains, its design and initial content.
• The communication tools to be used in the project, both internally and externally. These include
the templates to be used for presentations and reports, the selected internal collaboration tool
in the project, and the activities in terms of the use of external tools like social media.
Currently a land page website has been created while the official project website is being designed to be
developed and deployed. This deliverable describes the structure of both websites, as well as the different
content management and technical considerations being treated.
Tools and the procedures for communications are fully described in deliverable D7.1 Project Reference
Manual and Quality Plan.

5. PharmaLedger – 853992 | Deliverable D6.1 V3.0 | PUBLIC 5/13
1. INTRODUCTION
This deliverable describes the activities includes in part of Task 6.5 -dissemination and communication,
(WP6 Culture and Adoption), related to the set-up of the PharmaLedger project website, together with a
group of tools to be used for internal and external communication. The PharmaLedger website is one of
the relevant channels of the project supporting awareness activities, aiming at:
• Becoming an important source of information aggregation for the project.
• Providing real-time access to updated information about the project.
• Increasing exposure of the project and its activities through online means.
• Supporting the public image and branding of the project; and
• Stimulating online engagement of targeted stakeholder communities.
The PharmaLedger website communicates relevant and public information about the project and
integrates the project social networks: Twitter and LinkedIn (see external communication tools Section
4.2). Through the integration of social networks, we aim at increasing traffic in the project website,
communicate directly with target audience and approach future partners that engage with the project.
The website provides a user-friendly design and an easy-to-follow menu so visitors can understand briefly
its structure and can easily navigate throughout its entire content. PharmaLedger website complies with
W3C accessibility guidelines and it integrates a responsive design, adaptable to smartphones and tablets.
D6.1 PharmaLedger is structured in the following sections:
• Visual Identity: Description of the PharmaLedger brand and logo
• Description of the project website (accessible at http://www.pharmaledger.eu/ )
• Communications tools
2. VISUAL IDENTITY: PHARMALEDGER BRAND AND LOGO
The PharmaLedger Consortium has developed a professional logo, which expresses the values and
approach of the project (see D6.11. Dissemination and communication plan from the dissemination
inproject exploitation); this includes modern line cross square shape structure, connecting both; the dots
of digital technology and blockchain focus of the project; as well as the many interconnected stakeholders
within the pharmaceutical ecosystem.
The structure combines different tones and shades of blue and teal; representing freshness and
transparency (teal) with the professionalism, trust, authority and power (blue tones) that characterize the
blockchain innovative technology and the healthcare domain approach in the PharmaLedger project. The
following designs comprise the logo in its two versions: “primary” version (the full version of the logo with
project name and tag line) and a “second” version (the symbol- or monogram-only variation to use in
smaller spaces).
Figure 1: PharmaLedger Logos
The logo has been designed to work equally well on white and black backgrounds. A monochrome version
of the logo, in addition to various formats and sizes required for use on the website, printed materials and
other means, such as publications has also been developed.

6. PharmaLedger – 853992 | Deliverable D6.1 V3.0 | PUBLIC 6/13
PharmaLedger website will place the logo in a prominent side to reinforce the project brand identity,
including the website header and favicon (the small image beside your URL). Also, the project brand will
be reinforced using brand elements and logo in areas other than the navigation bar (e.g. the footer,
photos, etc.) and by using the logo colours throughout the website design.
3. PharmaLedger WEB SITE
The project website will be the public showcase where all the activities and results of the project will be
promoted. It will provide project overviews and highlights; up-to-date information on intermediate and
final project results, including public reports and publications; project events (e.g. meetings, conferences
and workshops, etc.).
3.1 Website Domain
The initial project website was created as a land page during the first month of the project. It has been
live since early February 2020 in the “pharmaledger.eu” domain.
To secure the web presence and branding of PharmaLedger, and considering future exploitation of results
and sustainability of the project, the following additional domain(s) have been acquired:
• Pharmaledger.eu (used)
• Pharmaledger.info (not used for the moment)
• Pharma-ledger.org (not used for the moment)
• Mypharmaledger.org (not used for the moment)
• Pharmaleger.es (not used for the moment)
• Mypharmaledger.eu (not used for the moment)
• Pharma-ledger.eu (not used for the moment)
3.2 Initial landing page or website setup
An initial landing page has been created as a simplified website while web site is under construction. The
landing page has been placed on this domain to provide overview of the project and contact information,
enabling users to voluntarily subscribe using only their email address for a communications mailing list.
This website will continue to be the first source of information until it is substituted by the official website.
Home page
Figure 2: PharmaLedger provisional webpage overview – home page

7. PharmaLedger – 853992 | Deliverable D6.1 V3.0 | PUBLIC 7/13
Subscribe section (as part of the home page)
Figure 3: PharmaLedger provisional webpage overview – home page subscribe
Press section
Figure 3: PharmaLedger provisional webpage overview – Press

8. PharmaLedger – 853992 | Deliverable D6.1 V3.0 | PUBLIC 8/13
About PharmaLedger
Figure 4: PharmaLedger provisional webpage overview – The project
Contact Us
Figure 6: PharmaLedger provisional webpage overview – Contact Us page

9. PharmaLedger – 853992 | Deliverable D6.1 V3.0 | PUBLIC 9/13
3.3 Design and development of the PharmaLedger website
The design of the project website includes the following sections and pages, all aimed at maximising the
impact in disseminating and communicating the activities and results of the project.
Home Page: The home page presents the PharmaLedger project as well as an overview of the entire
website such as information about the project, blockchain, partners, latest news, latest social media
activity and upcoming events related to the project.
Title Content
Horizontal Menu • Blockchain technology
• About US
• News
• Activities
• Events
• For Patients
• Advisory board
• Contact
Content Picture and text highlighting the 3 research areas (DRAs) and use cases
of the project
Social Media The presence in social networks are intended to better position the
project within search engines (SEO) as well as to dynamize content
generated during the project lifecycle through social sharing tools.
PharmaLedger presence in social networks can be accessed from the
website, which redirects visitors to the PharmaLedger Social media links.
Login in For consortium members only to link with the internal communication
tools and platform (e.g. Teams communication tool).
Mailing List signup/
Subscribe
Presents the contact information of the Project Coordinators as well as
provides email services to request information, subscribe to latest news,
contact the project to engage in project`s actions or un-subscription. All
information is manged through the Data Management Plan which
enables GDPR compliance.
Logos • PharmaLedger logos (headers and through website)
• EU flag with description: This project has received funding from the
European Union’s Horizon 2020 research and innovation programme
Innovative Medicines Initiative (IMI) 2 Joint Undertaking under grant
agreement No H2020-JTI-IMI2-GA- 853992
• IMI logo
• EFPIA logo
• In addition, PharmaLedger will display the W3C accessibility
guidelines compliance icon
Sub – pages
Title Content
Blockchain What is it / how it works/ Benefits
Frequently Asked Questions (FAQ)
About us What is PharmaLedger-Blockchain Enabled Healthcare
• Objectives
• Project organization
• Partners’ short profile and project role

10. PharmaLedger – 853992 | Deliverable D6.1 V3.0 | PUBLIC 10/13
Title Content
• The Consortium – history timeline/ model
/funding/sponsorship/leadership and coordination
Project Activities Focus Areas :
• Supply Chain
• Health Data Market Place
• Clinical Trials
Work Packages
News & Events • News feed / press releases /media highlights: this shall integrate a
multi-author blog format with RSS and newsletter subscription
capabilities.
• Events/Conferences: list of relevant events and conferences
• Trainings/Brokerage: this shall include guidelines and/or material
produced in PharmaLedger for training and brokerages.
Advisory Board Presents the PharmaLedger External Experts Advisory Board
Project results & Links This section gathers all public information about the PharmaLedger project
that can be downloaded by visitors such as Dissemination Materials,
Publications, Articles and Public Deliverables. It contains:
• Downloads (e.g. it shall comprise the project communication material
such as press releases, slides, postcard, flyers, among others)
• Publications and deliverables: comprise public and relevant
documentation related to the project such as deliverables, scientific
papers, white papers or articles and press releases published about the
project.
Also, this area shall link with other related EU and/or IMI funded projects
FAQ Project Frequently Asked Questions (FAQ)
3.4 Website Content Management
A content management back office solution will be provided to support the content management, online
traffic and related technical services. For administration purposes, the following management categories
are foreseen to be included in the website’s back office: user management, content upload management,
menu and content categories management, back up management and websites statistics.
All partners are responsible for content generation and integrity, contributing to the website and social
networks updates with relevant information as required by the PharmaLedger Description of Action
(DoA). The dissemination and communication leaders TVS and Novartis, coupled with task 6.1 leader ONO,
are responsible for the operational and technical support and maintenance of the website after its launch.
To better support website activities, the PharmaLedger Consortium decided to partner with a Digital
Marketing Agency in the provision of the Project Website (design, development, content creation etc.),
supporting a content-based dissemination strategy approach. Further services for inbound marketing via
social media will be evaluated and dependant on the dissemination and communication plan established
in D6.11 Dissemination and in project exploitation plan.
For the selection of this provider the requirements were defined in the WP6 together with the consortium
and sent to different agencies as request of quotation. The offers received (5 agencies) were analysed
based on “value for money”, assessing the offers in terms of development time, cost and supporting
services offered.

11. PharmaLedger – 853992 | Deliverable D6.1 V3.0 | PUBLIC 11/13
3.5 Monitoring and control
From content management perspective, the PharmaLedger website and social networks will be constantly
monitored for content updating, community interaction and technical updates to enhance its features
and user experience. Before being implemented, all changes are evaluated based on user behaviour
analyses, in order to optimize web traffic and visibility, user engagement and best visiting experience for
the target groups.
Both the project’s website and social networks will continuously be monitored using web analytic tools to
identify the quantitative/qualitative KPIs such as website's visits, unique visitors, time per visit, traffic
source and other key metrics that will enhance visitors’ experience and engagement.
From technical perspective, the PharmaLedger website will be continuously updated and monitored to
avoid technical problems and downtime. All new pages and services will be pre-tested in a non-public
area of the webserver.
3.6 Website Technical Aspects
The website has been designed to have a hierarchical organization, supported by dynamic content
management and web publishing tools. TVS, NVS and ONO are responsible of the technical infrastructure
and developing and hosting the website, as well as for managing the website through the project lifecycle.
The web is being developed using Open Source technologies(e.g. PhP and MySQL environments are being
evaluated). The interface and overall technical operation and functionalities of the website have been
developed using Wordpress as the Content Management System (CMS), publishing platform. Primary
Language for the website is UK English
3.7 Security and back-up
For security purposes partners’ accessibility to the communication tools and social networks through
the website is based on a username/password system. Only partners with the given username and
password can access these dissemination channels. Each username and password are communicated
separately to each partner.
Security updates to the operative system as well as all used software systems will be applied regularly.
Backups of the systems installation and content will be done regularly, at least every two weeks. Restore
of the system in case of a fatal system crash or hardware defect shall be provided within one day.
4. COMMUNICATION TOOLS
4.1 Internal communication tools
The PharmaLedger project has established a set of procedures and tools to ensure a good and effective
internal communication among all the member in the Consortium. These include:
• Emails and mailing lists, as the main communication method for collaboration among
geographically distributed partners. A set of personalized Pharmledger.eu domain emails
addresses have been created to reinforce brand and engagement with the project; these emails
addresses allow to interact from project and management perspective with other organisations,
entities and projects and/or among PharmaLedger WPs mailing lists (e.g.
contact@pharmaledger.eu; WP5@pharmaledger.eu, etc)
• Collaboration Platform, to share documents and information, but also to establish internal
discussions and working together on different aspects of the project (presentations, workshops,
reports, etc.). Microsoft Teams has been selected as the internal collaboration platform. The
platform is in place since February 10th
, 2020. The 29 PharmaLedger partners are actively
participating through 158 members.

12. PharmaLedger – 853992 | Deliverable D6.1 V3.0 | PUBLIC 12/13
• Video conference system, the zoom platform (https://zoom.us/signin) has been selected to hold
virtual meetings, workshops and teleconferences along the different WPs of the project.
These tools and the procedures defined for its use within the project are fully described in deliverable
D7.1 Project Reference Manual and Quality Plan.
Figure 5: Microsoft Teams tool
4.2 External communication tools
Different external communication channels and tools have been created for PharmaLedger. Evaluation of
implementation of other communication tools will be assessed coupled with the strategy being defined
in the dissemination and communication plan (D6.11).
In order to share the project results and created multimedia content the following social media channels
have been created to support dissemination and communication:
• Twitter: www.twitter.com/pharmaledger
• LinkedIn: www.linkedin.com/company/pharmaledger
4.2.1 Twitter
PharmaLedger created a twitter profile @PharmaLedger in January, 2020. Currently it has 74 followers
and 8 tweets.
Figure 8: @PharmaLedger Twitter page

13. PharmaLedger – 853992 | Deliverable D6.1 V3.0 | PUBLIC 13/13
4.2.2 LinkedIn
The ‘PharmaLedger’ LinkedIn profile has been created in January 2020; aiming at targeting the
professional-oriented community. During the first three months of the project, 174 followers have joined
the group.
Figure 9: LinkedIn profile
4.2.3 LinkedIn Engagement Group
The LinkedIn engagement group was created to provide the professional-oriented audience with an online
space for networking and discussion.
Figure 10: PharmaLedger Engagement Group in LinkedIn
In addition to these social networks, a News feed, press releases and media highlights will be integrated
in the News page of the project’s website, together with information about Events, Conferences,
Trainings, etc. This will allow the project to share its latest developments and reach to a wide audience.
Finally, the project website offers a subscription to email communication together with an email
functionality to contact the members of the project: contact@pharmaledger.eu.